←Tourette Syndrome

Study register · detail Systematische Review + Meta-Analyse · Tourette Syndrome · 2026

Cannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management

Mann et al. ·Neuroscience Impact 2.5

Clear benefit GRADE High 0 citations

Samplek = 8 Studien
n = 306 Pat.

Durationuntil 2 July 2025

ControlPlacebo or no control

EndpointYGTSS

Blindingunklar

DesignSystematische Review + Meta-Analyse

Key finding

CBMs significantly reduced tic severity and premonitory urge in Tourette syndrome compared to baseline values.

Summary

Systematic review and meta-analysis across k=8 studies (7 in the meta-analysis, n=306 adult Tourette patients) on cannabis-based medicines in Tourette syndrome. Significant reduction in tic severity (YGTSS, MD −13,29; 95% CI −21,67 to −4,91; p=0,002) as well as premonitory urge (PUTS, MD −4,09; 95% CI −7,24 to −0,93; p=0,01). Conclusion: promising evidence for tic reduction; larger placebo-controlled studies needed to confirm efficacy and safety.

PopulationAdults with Tourette syndrome, pooled n=306

InterventionCannabis-based medicines (CBMs, various cannabinoids/applications)

ControlPlacebo (in some sub-studies) or no control

OutcomeSignificant reduction in YGTSS scores (MD -13,29; 95% CI -21,67 to -4,91; p=0,002) and PUTS scores (MD -4,09; 95% CI -7,24 to -0,93; p=0,01)

Confidence in the evidence

High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile

Sample size ★★★★★

Blinding —

Effect size Clear benefit

Citations / year ★★★★★

Authors

Mann GS, Gadelmawla AF, Dway A, Fayaz FH, Kebede EA, Varadharaj NK, Akram A, Khan A, Azuwike UB, Sampangi BK, Ogundijo OA

DOI 10.1016/j.neuroscience.2026.05.044↗

Design: Systematische Review + Meta-Analyse

Abstract

Tourette syndrome (TS) involves motor and vocal tics, often with OCD and ADHD. Cannabis-based medicines (CBMs) are a potential therapy via the endocannabinoid system. This systematic review and meta-analysis evaluated CBM efficacy in TS. Databases (PubMed, Google Scholar, ScienceDirect, Cochrane) were searched for cohort studies and RCTs up to 2 July 2025. From 1,105 screened articles, eight studies met inclusion criteria for the review and seven were included in the meta-analysis, involving 306 adult TS patients. CBMs significantly reduced YGTSS scores (MD -13.29, 95% CI -21.67 to -4.91, p=0.002) and PUTS scores (MD -4.09, 95% CI -7.24 to -0.93, p=0.01). Larger placebo-controlled trials are needed. PROSPERO CRD420251088633. Source: PubMed PMID 42229830.

The impediment to action advances action. — Marcus Aurelius